ライフサイエンスコーパス: cytomegalovirus

1 lution of influenza virus, dengue virus, and cytomegalovirus.

2 dones showed mild activity against the human cytomegalovirus.

3 us and the 310 "Delta"-shaped CATCs in human cytomegalovirus.

4 berculosis, Salmonella, Cryptosporidium, and cytomegalovirus.

5 with varicella-zoster virus (4.9%), 27 with cytomegalovirus (26.5%), and 1 with Epstein-Barr virus (

6 s pneumoniae (54 [20%]), HIV (40 [15%]), and cytomegalovirus (34 [12%]), and multiple infections were

7 , including Aspergillus fumigatus (1.4%) and cytomegalovirus (6%), were rare, scattering over 12 mont

8 of virus-employed countermeasures.IMPORTANCE Cytomegalovirus (a betaherpesvirus) is a master at manip

9 Immunohistochemistry for cytomegalovirus, adenovirus, and simian virus 40 were ne

10 Cytomegalovirus and EBV mismatch were avoided in 90% (9/

11 Cytomegalovirus and Epstein-Barr virus reactivations wer

12 to prior infections, and higher incidence of cytomegalovirus and herpes simplex virus 1, possibly inf

13 d hypersusceptibility to infection by murine cytomegalovirus and multiple defects of lymphoid develop

14 bda"-shaped dimeric CATCs observed in murine cytomegalovirus and the 310 "Delta"-shaped CATCs in huma

15 ite of persistence for both human and murine cytomegaloviruses, and salivary secretions appear to pla

16 Cytomegalovirus anterior uveitis is not uncommon in pati

17 is virus (LCMV) vectors expressing the human cytomegalovirus antigens glycoprotein B (gB) and the 65-

18 tivation states in animals infected by mouse cytomegalovirus by combining Ifnb1 reporter mice with fl

19 and specific for the detection of congenital cytomegalovirus (cCMV) in universal screening studies.

20 Congenital cytomegalovirus (cCMV) infection is a leading cause of h

21 Congenital cytomegalovirus (cCMV) infection is a major cause of chi

22 paucity of data on the burden of congenital cytomegalovirus (cCMV) infections in low- and middle-inc

23 A vaccine against congenital cytomegalovirus (cCMV) is a high priority.

24 en seronegative before pregnancy, congenital cytomegalovirus (cCMV)-related sequelae are exclusively

25 Cytomegalovirus (CMV) (18.3%), human herpesvirus 6 (HHV-

26 Cytomegalovirus (CMV) almost universally infects persons

27 al viruses such as Epstein-Barr virus (EBV), cytomegalovirus (CMV) and Herpes simplex virus.

28 exhibit memory-like recall responses against cytomegalovirus (CMV) and human immunodeficiency/virus s

29 Opportunistic infections including cytomegalovirus (CMV) are a major cause of morbidity and

30 Human herpesvirus 6 (HHV-6) and cytomegalovirus (CMV) are population-prevalent betaherpe

31 Cytomegalovirus (CMV) can cause severe disease in childr

32 Human cytomegalovirus (CMV) causes a wide array of disease to

33 Vaccines based on cytomegalovirus (CMV) demonstrate protection in animal m

34 Letermovir (LET), a cytomegalovirus (CMV) deoxyribonucleic acid (DNA) termin

35 Cytomegalovirus (CMV) establishes a lifelong infection f

36 Cytomegalovirus (CMV) has been implicated in glioblastom

37 Improving cytomegalovirus (CMV) immune-risk stratification in kidn

38 Maternal preconceptional cytomegalovirus (CMV) immunity does not protect the fetu

39 ork model can accurately diagnose the latent cytomegalovirus (CMV) in healthy individuals, even when

40 The antimalarial agents artemisinins inhibit cytomegalovirus (CMV) in vitro and in vivo, but their ta

41 umoral immunity on the prevention of primary cytomegalovirus (CMV) infection after hematopoietic cell

42 Control of cytomegalovirus (CMV) infection after solid organ transp

43 Previous studies on the association between cytomegalovirus (CMV) infection and cardiac allograft va

44 Previous studies on the association between cytomegalovirus (CMV) infection and cardiac allograft va

45 Numerous candidate vaccines against cytomegalovirus (CMV) infection and disease are in devel

46 This work provides specific tools to combat cytomegalovirus (CMV) infection and helps illuminate a g

47 munosuppression, leading to a higher risk of cytomegalovirus (CMV) infection compared with anti-inter

48 We have previously shown that acute cytomegalovirus (CMV) infection disrupts the induction o

49 After primary maternal cytomegalovirus (CMV) infection during pregnancy, infant

50 trials, 120 patients received maribavir for cytomegalovirus (CMV) infection failing conventional the

51 tor, has been approved for the prevention of cytomegalovirus (CMV) infection in hematopoietic stem ce

52 Cytomegalovirus (CMV) infection is a major cause of morb

53 Cytomegalovirus (CMV) infection is a risk factor for chr

54 Cytomegalovirus (CMV) infection is a serious complicatio

55 The natural history of cytomegalovirus (CMV) infection is complex.

56 Chronic cytomegalovirus (CMV) infection leads to long-term maint

57 Cytomegalovirus (CMV) infection remains an important cau

58 We hypothesized that early cytomegalovirus (CMV) infection was associated with incr

59 between posttransplant PCP and 3 variables: cytomegalovirus (CMV) infection, allograft rejection, an

60 factors and infectious exposures, including cytomegalovirus (CMV) infection.

61 ocytes capable of "adaptive" responses after cytomegalovirus (CMV) infection.

62 Human cytomegalovirus (CMV) infections comprise a leading caus

63 Cytomegalovirus (CMV) infections in hematopoietic cell t

64 Cytomegalovirus (CMV) infections that are refractory or

65 The development of therapeutics for cytomegalovirus (CMV) infections, while progressing, has

66 Cytomegalovirus (CMV) is a beta-herpesvirus that establi

67 Cytomegalovirus (CMV) is a herpesvirus capable of causin

68 ach against human cCMV attractive.IMPORTANCE Cytomegalovirus (CMV) is a leading cause of congenital d

69 Cytomegalovirus (CMV) is a major cause of infection-rela

70 Cytomegalovirus (CMV) is a ubiquitous betaherpesvirus th

71 Human cytomegalovirus (CMV) is a ubiquitous pathogen that caus

72 Cytomegalovirus (CMV) is the commonest cause of congenit

73 Cytomegalovirus (CMV) is the most common congenital infe

74 Despite the use of a cytomegalovirus (CMV) prevention strategy of antiviral p

75 ntary DNA genome copy under the control of a cytomegalovirus (CMV) promoter confirms autonomous genom

76 Adenoviral firefly luciferase vector with a cytomegalovirus (CMV) promotor to porcine donor hearts p

77 Valganciclovir has been widely used for cytomegalovirus (CMV) prophylaxis in solid-organ transpl

78 sk kidney transplant (KT) recipients without cytomegalovirus (CMV) prophylaxis.

79 Cytomegalovirus (CMV) reactivation has been described in

80 Cytomegalovirus (CMV) reactivation remains one of the mo

81 Cytomegalovirus (CMV) remains an important pathogen in t

82 Cytomegalovirus (CMV) remains associated with poor outco

83 individual virions of the human herpesvirus cytomegalovirus (CMV) showed that virion-to-virion level

84 Infection with multiple cytomegalovirus (CMV) strains (mixed infection) was repo

85 The considerable public health burden due to cytomegalovirus (CMV) supports current interest in vacci

86 Several cytomegalovirus (CMV) vaccine candidates are under devel

87 Cytomegalovirus (CMV) viral loads overall were 0.29 log

88 Cytomegalovirus (CMV) viremia may be associated with inc

89 Cytomegalovirus (CMV) viremia may be associated with inc

90 The incidence of cytomegalovirus (CMV) viremia was 0.5 in the MUD group a

91 ding poliovirus, herpes simplex virus (HSV), cytomegalovirus (CMV), and influenza.

92 d have missed an additional enterovirus, one cytomegalovirus (CMV), and two HHV-6 diagnoses.

93 th AD while other related viruses, including cytomegalovirus (CMV), Epstein-Bar virus and human herpe

94 Reactivation of cytomegalovirus (CMV), Epstein-Barr virus (EBV), and var

95 iruses, such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV), were detected at comparable level

96 Using a cytomegalovirus (CMV)-cre strain, Wasf3 constitutively w

97 Cytomegalovirus (CMV)-infection remains a major cause of

98 Forty-two cytomegalovirus (CMV)-positive and 41 Epstein-Barr virus

99 .26), study heterogeneity index (I)= 23.4%), cytomegalovirus (CMV)-related illnesses (pOR = 3.14 (2.3

100 ection and mortality, but is only present in cytomegalovirus (CMV)-seropositive individuals.

101 To retarget cytomegalovirus (CMV)-specific CD8(+) T cells against tu

102 antiviral prophylaxis (AP) on development of cytomegalovirus (CMV)-specific neutralizing antibody (nA

103 Triplex vaccine was developed to enhance cytomegalovirus (CMV)-specific T cells and prevent CMV r

104 e living with HIV (PLWH) are coinfected with cytomegalovirus (CMV).

105 benzimidazole riboside with activity against cytomegalovirus (CMV).

106 ortant target for vaccine strategies against cytomegalovirus (CMV).

107 w focuses on recent advances in the field of cytomegalovirus (CMV).

108 itis A virus (HAV), measles virus (MeV), and cytomegalovirus (CMV).

109 The most frequently detected targets were cytomegalovirus (CMV, n = 139, 41%), Mycobacterium tuber

110 ose of other chronic viral infections (i.e., cytomegalovirus [CMV] and Epstein-Barr virus [EBV]).

111 C virus [HCV], Epstein-Barr virus [EBV], and cytomegalovirus [CMV]) have limited breadth and diversit

112 ) viruses (adenovirus [ADV], BK virus [BKV], cytomegalovirus [CMV], Epstein-Barr virus [EBV], human h

113 a composite outcome of infection (including cytomegalovirus [CMV], herpes simplex I/II or varicella

114 Although cytomegaloviruses (CMVs) are species-specific, the study

115 Cytomegaloviruses (CMVs) are ubiquitous pathogens known

116 Recognition of DNA viruses, such as cytomegaloviruses (CMVs), through pattern-recognition re

117 In an unusual twist, human cytomegalovirus co-opts the antiviral radical SAM enzyme

118 l response of neurons to infection, as human cytomegalovirus did not downregulate DBH expression.

119 t or refractory cytomegalovirus infection or cytomegalovirus disease is a challenge.

120 d during treatment of symptomatic congenital cytomegalovirus disease, but their predictive value is u

121 munosuppression may be at increased risk for Cytomegalovirus disease, notably Cytomegalovirus retinit

122 ological abnormalities, lymphadenopathy, and cytomegalovirus disease.

123 Cytomegalovirus DNA became undetectable and there was pa

124 3 accurately detects BK polyomavirus DNA and cytomegalovirus DNA from patient-derived blood and urine

125 Both Cytomegalovirus DNA in plasma and aqueous humor were pos

126 Cytomegalovirus DNAemia was detected 11.5 days earlier b

127 We report a case of cytomegalovirus encephalitis in a hematopoietic stem cel

128 rospinal fluid is warranted in subjects with cytomegalovirus encephalitis, owing to the low penetrati

129 In particular, cytomegaloviruses encode large arsenals of molecules tha

130 Human Cytomegalovirus encodes several factors that limit host

131 Common viral targets include cytomegalovirus, Epstein-Barr virus, and adenovirus, tho

132 s frequent than T cells with specificity for cytomegalovirus, Epstein-Barr virus, or influenza virus.

133 Cytomegalovirus, Escherichia coli, group B Streptococcus

134 s a decreased proportion of viral (including cytomegalovirus), fungal (including Aspergillus spp. and

135 es, which revealed the extent to which human cytomegalovirus generates nuclear polarity through a vir

136 ecies specificity and limited homology among cytomegalovirus genomes.

137 Cytomegalovirus genotyping was performed to identify LET

138 ) viral vaccine strain based on a guinea pig cytomegalovirus (GPCMV) capsid mutant was evaluated.

139 rr virus 36% in saliva and 39% in GCF; human cytomegalovirus (HCMV) 11% in GCF; varicella zoster viru

140 Of the human herpesviruses, cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) both

141 herpes simplex virus 1 (HSV-1), HSV-2, human cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) entr

142 hannel inhibitors for activity against human cytomegalovirus (HCMV) and identified the voltage-gated

143 Recent evidence highlights human cytomegalovirus (HCMV) and immune activation as risk fac

144 spase-8 activation (vICA) conserved in human cytomegalovirus (HCMV) and murine CMV (MCMV) prevents th

145 ruses varicella-zoster virus (VZV) and human cytomegalovirus (HCMV) are endemic to humans.

146 widely held that clinical isolates of human cytomegalovirus (HCMV) are highly cell associated, and m

147 Human cytomegalovirus (HCMV) can cause congenital infections,

148 Human cytomegalovirus (HCMV) can persistently infect humans, b

149 Human cytomegalovirus (HCMV) causes a lifelong infection throu

150 Human cytomegalovirus (HCMV) causes severe disease in infants

151 Human cytomegalovirus (HCMV) causes substantial disease in tra

152 to restrict HCMV infections.IMPORTANCE Human cytomegalovirus (HCMV) continues to cause serious and of

153 jor immediate early promoter (MIEP) of human cytomegalovirus (HCMV) drives the expression of crucial

154 ine to prevent maternal acquisition of human cytomegalovirus (HCMV) during pregnancy is a primary str

155 The human cytomegalovirus (HCMV) endoplasmic reticulum (ER)-reside

156 Human cytomegalovirus (HCMV) entry into cells where it initiat

157 ditionally, we report that GA inhibits human cytomegalovirus (HCMV) genome replication and Zika virus

158 ncing efforts have led to estimates of human cytomegalovirus (HCMV) genome-wide intrahost diversity t

159 Human cytomegalovirus (HCMV) glycoproteins H and L (gH/gL) can

160 Human cytomegalovirus (HCMV) has been linked to the triggering

161 hich showed antiviral activity against Human Cytomegalovirus (HCMV) in our previous work, could restr

162 Congenital human cytomegalovirus (HCMV) infection causes a broad spectrum

163 The critical consequences of human cytomegalovirus (HCMV) infection in the transplant popul

164 Human cytomegalovirus (HCMV) infection is associated with neur

165 ividuals, immune control of persistent human cytomegalovirus (HCMV) infection is effectively mediated

166 ltimately viral persistence.IMPORTANCE Human cytomegalovirus (HCMV) infection is endemic throughout t

167 ssemination within the host.IMPORTANCE Human cytomegalovirus (HCMV) infection is endemic throughout t

168 Human Cytomegalovirus (HCMV) infection modulates cellular meta

169 Human cytomegalovirus (HCMV) infection remains an important ca

170 I IFN and increased susceptibility to human cytomegalovirus (HCMV) infection.

171 Human Cytomegalovirus (HCMV) infects over half the world's pop

172 Human cytomegalovirus (HCMV) is a beta-herpesvirus that has co

173 Human cytomegalovirus (HCMV) is a common beta-herpesvirus caus

174 Human cytomegalovirus (HCMV) is a common opportunistic pathoge

175 that occur during infection.IMPORTANCE Human cytomegalovirus (HCMV) is a common pathogen that asympto

176 may be a therapeutic target.IMPORTANCE Human cytomegalovirus (HCMV) is a herpesvirus present in up to

177 efficiency of virus spread.IMPORTANCE Human cytomegalovirus (HCMV) is a herpesvirus that leads to se

178 Human cytomegalovirus (HCMV) is a large DNA herpesvirus that i

179 HCMV-induced birth defects.IMPORTANCE Human cytomegalovirus (HCMV) is a leading cause of central ner

180 The herpesvirus human cytomegalovirus (HCMV) is a leading cause of congenital

181 Human cytomegalovirus (HCMV) is a major cause of morbidity and

182 Human cytomegalovirus (HCMV) is a prevalent betaherpesvirus th

183 Human cytomegalovirus (HCMV) is a significant source of morbid

184 Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus that

185 Human cytomegalovirus (HCMV) is a ubiquitous human herpesvirus

186 Human cytomegalovirus (HCMV) is a ubiquitous pathogen that can

187 Human cytomegalovirus (HCMV) is a ubiquitous pathogen that enc

188 Human Cytomegalovirus (HCMV) is a ubiquitous pathogen that has

189 Human cytomegalovirus (HCMV) is a ubiquitous pathogen that lat

190 Human cytomegalovirus (HCMV) is a ubiquitous pathogen that und

191 Human cytomegalovirus (HCMV) is an important human pathogen an

192 s II transactivator (CIITA).IMPORTANCE Human cytomegalovirus (HCMV) is an opportunistic herpesvirus t

193 irect engagement of virions.IMPORTANCE Human cytomegalovirus (HCMV) is major pathogen of nonimmunocom

194 to the viral dissemination strategy of human cytomegalovirus (HCMV) is the induction of monocyte surv

195 Human cytomegalovirus (HCMV) is the most common infectious cau

196 uated in preclinical models.IMPORTANCE Human cytomegalovirus (HCMV) is the most common infectious cau

197 Human cytomegalovirus (HCMV) latency and reactivation rely on

198 Human progenitor cells (HPCs) support human cytomegalovirus (HCMV) latency, and their differentiatio

199 Human cytomegalovirus (HCMV) manipulates cellular processes as

200 Human cytomegalovirus (HCMV) manipulates many aspects of host

201 Human cytomegalovirus (HCMV) may cause severe infections in lu

202 Various aspects of human cytomegalovirus (HCMV) pathogenesis, including its abili

203 A human cytomegalovirus (HCMV) pentameric glycoprotein complex (

204 resolution 1.48 angstrom structure of human cytomegalovirus (HCMV) pUL50-pUL53.

205 Infection with human cytomegalovirus (HCMV) remains a significant cause of mo

206 egulation in infected cells.IMPORTANCE Human cytomegalovirus (HCMV) replicates in several cell types

207 Human cytomegalovirus (HCMV) replication requires host metabol

208 ricting ribosome biogenesis stimulated human cytomegalovirus (HCMV) replication without suppressing t

209 Little is known about the human cytomegalovirus (HCMV) tegument protein UL88.

210 istinctly regulate the activity of the human cytomegalovirus (HCMV) transactivator immediate early 2

211 The human cytomegalovirus (HCMV) UL138 protein downregulates the c

212 A human cytomegalovirus (HCMV) vaccine is urgently needed to pro

213 e of human-restricted viruses, such as human cytomegalovirus (HCMV), a leading cause of congenital in

214 scripts of hepatitis B virus (HBV) and human cytomegalovirus (HCMV), generated via a similar mechanis

215 As with human cytomegalovirus (HCMV), GPCMV uses a specific cell recep

216 Human cytomegalovirus (HCMV), like many other DNA viruses, can

217 poor prognosis in colon cancer, and in human cytomegalovirus (HCMV)-infected fibroblasts, where the R

218 ughout infection with the herpesvirus, human cytomegalovirus (HCMV).

219 unger than 1 month diagnosed with-congenital cytomegalovirus, herpes simplex virus (HSV), varicella z

220 ouble weight compared to class B infections (cytomegalovirus, herpes simplex virus-1/2, human herpesv

221 -4.85]) and opportunistic infections such as cytomegalovirus (HR, 3.98 [95% CI, 1.40-11.26]), varicel

222 d systemic injections of foscarnet, and anti-Cytomegalovirus human immunoglobulin.

223 e sequence between distinct strains of human cytomegalovirus (human herpesvirus 5) and show that gene

224 like those of humans with cytomegalovirus, human immunodeficiency virus (even when

225 rocally, several unrelated viruses including cytomegalovirus, human immunodeficiency virus, influenza

226 ntigen 1 (EBNA-1), diffuse early antigen, or cytomegalovirus IgG levels and offspring MS risk.

227 tional divergence between homologous primate cytomegalovirus immunevasins and suggest that the capaci

228 iterature on the diagnosis and management of cytomegalovirus in patients after HSCT and in patients r

229 ommendations of the ECIL 7 for management of cytomegalovirus in patients with haematological malignan

230 .IMPORTANCE Varicella-zoster virus and human cytomegalovirus infect a majority of the global populati

231 The exact contribution of congenital cytomegalovirus infection (cCMVI) to permanent hearing l

232 liver disease (HR, 2.18; 95% CI, 1.29-3.67), cytomegalovirus infection (HR, 1.89; 95% CI, 1.08-3.3),

233 in 46 [30%] and 42 [28%], respectively), and cytomegalovirus infection (in 39 [26%] and 31 [21%]).

234 re features were not observed during chronic cytomegalovirus infection in an independent cohort.

235 ent of patients with resistant or refractory cytomegalovirus infection or cytomegalovirus disease is

236 infection (OR = 7.75; 95% CI = 1.60-37.57), cytomegalovirus infection or disease (OR = 2.67; 95% CI

237 Congenital cytomegalovirus infection was associated with birthweigh

238 d in natural killer (NK) cells responding to cytomegalovirus infection, and consider the requirements

239 , respectively, is in development to prevent cytomegalovirus infection.

240 as discussed at the 2018 workshop entitled "Cytomegalovirus Infection: Advancing Strategies for Prev

241 l, letermovir reduced clinically significant cytomegalovirus infections (CS-CMVi) and all-cause morta

242 Cytomegalovirus is a worldwide-distributed human pathoge

243 n increasing number of reports indicate that cytomegalovirus is also a potentially important pathogen

244 he way to a successful vaccine against human cytomegalovirus is hampered by the peculiar biology of t

245 in hospital discharges coded with congenital cytomegalovirus is most likely due to the introduction o

246 Cytomegalovirus is one of the most important infections

247 nfection of Zbtb32(-/-) chimeras with murine cytomegalovirus led to nearly 20-fold higher antigen-spe

248 nce status, donor age, HLA match, sex match, cytomegalovirus match, conditioning intensity, type of T

249 lytic activity, and mice infected with mouse cytomegalovirus (MCMV) displayed elevated titers in the

250 Mouse cytomegalovirus (MCMV) infection promotes a rapid host-m

251 Early during mouse cytomegalovirus (MCMV) infection, NK cells up-regulated

252 naline, in modulating host response to mouse cytomegalovirus (MCMV) infection.

253 Here we show that murine cytomegalovirus (MCMV), a prototypic beta-herpesvirus, h

254 r infection with the beta-herpesvirus murine cytomegalovirus (MCMV).

255 rticipated in KPD for the following reasons: cytomegalovirus mismatch (18.5% [10/54]), Epstein-Barr v

256 rs and chronic graft dysfunction (5 points); cytomegalovirus mismatch (4 points); and CD8+ T-cell cou

257 ovirus [n = 2]), hepatitis B virus (n = 10), cytomegalovirus (n = 9), Epstein-Barr virus (n = 5), and

258 HB-101 was tested in cytomegalovirus-naive, healthy adults in a randomized, d

259 ient to elicit dose-dependent gB-binding and cytomegalovirus-neutralizing antibodies (Abs).

260 The use of different quantitative cytomegalovirus nucleic acid tests may affect direct pat

261 cells or in cells infected with either human cytomegalovirus or Kaposi's sarcoma-associated herpesvir

262 Postnatally acquired cytomegalovirus (pCMV) infection through breast milk (BM

263 HR, 2.97 [95% CI, 1.51-5.83]; P = .002), and cytomegalovirus pneumonitis (HR, 3.76 [95% CI, 1.23-11.4

264 % confidence interval [CI], 26.7-204) and in cytomegalovirus-positive recipients (OR = 3.70; 95% CI,

265 strain Paraiba/2015 under the control of the cytomegalovirus promoter was complexed with a commercial

266 trial of twice-weekly oral brincidofovir for cytomegalovirus prophylaxis after allogeneic HCT to stud

267 The patient had had several episodes of Cytomegalovirus reactivation subsequent to the introduct

268 ed VDJ segments to generate invariant/public cytomegalovirus-reactive CDR3 sequences (TRGV8-TRJP1-CAT

269 Cytomegalovirus remained detectable by cobas CMV in 44.2

270 of belatacept-associated multidrug-resistant Cytomegalovirus retinitis in a kidney transplant recipie

271 Cytomegalovirus retinitis is a serious infection because

272 Cytomegalovirus retinitis is an uncommon opportunistic i

273 The occurrence of Cytomegalovirus retinitis may help improve the selection

274 on, 18 months after the initial diagnosis of Cytomegalovirus retinitis.

275 ed risk for Cytomegalovirus disease, notably Cytomegalovirus retinitis.

276 terleukin-10 (IL-10) manifest delayed rhesus cytomegalovirus (RhCMV) acquisition and altered immune r

277 Rhesus cytomegalovirus (RhCMV) strain 68-1-vectored simian immu

278 raft, - mismatch, comorbidity index >=3, and cytomegalovirus seropositivity (P < .001 for all variabl

279 Age <18 years, recipient cytomegalovirus seropositivity, absolute lymphocyte coun

280 betes stratified by HIV status, adjusted for cytomegalovirus serostatus and traditional risk factors.

281 itioning regimen, patient and donor sex, and cytomegalovirus serostatus.

282 ganize the ER, while the homolog from rhesus cytomegalovirus shows neither activity.

283 ssed the safety and therapeutic potential of cytomegalovirus-specific (CMV-specific) ACT in an adjuva

284 Cytomegalovirus-specific immune responses were boosted a

285 hritidis mitogen, on influenza virus- and/or cytomegalovirus-specific memory TCD8 could be monitored.

286 HB-101 was well tolerated and induced cytomegalovirus-specific polyfunctional CD8 T-cell and n

287 ses were lost after transplantation, whereas cytomegalovirus-specific responses were detectable.

288 quencing and structural affinity analyses of cytomegalovirus-specific T cells, and through the genera

289 al insight into the mechanism by which human cytomegalovirus subverts viperin; they also provide a bi

290 ossible to infect model organisms with human cytomegalovirus, the aim of this study was to develop a

291 we review the diverse strategies adopted by cytomegaloviruses to target immune pathways and outline

292 Additionally, we found that the chimpanzee cytomegalovirus UL148 homolog suppresses surface present

293 nd, possibly, by evolution, since chimpanzee cytomegalovirus UL148 retains CD58 but does not remodel

294 ficiency, mechanical ventilation, high-level cytomegalovirus viremia, gram-negative bacteremia, invas

295 mus variability was not associated with late cytomegalovirus viremia.

296 His cytomegalovirus was multi-drug resistant, and was treate

297 mulating infection of the human herpesvirus, cytomegalovirus, we hypothesize that virus-mediated disr

298 a from the prototypic betaherpesvirus, human cytomegalovirus, we uncover numerous uORFs and iORFs con

299 By contrast, receptors for Zika virus and cytomegalovirus, which cause congenital infections, are

300 affinity during the course of infection with cytomegalovirus, which elicits large T cell populations